Cantourage Reports Strong Q1 2025 Earnings with Boosted Profitability

Berlin-based Cantourage Group SE has announced a significant increase in both profitability and revenue for the first quarter of 2025. The medical cannabis company achieved an EBITDA margin between 11 and 13%, according to preliminary data. Cantourage's revenue in this period exceeded EUR 25 million, with cumulative revenue surpassing EUR 36 million by the end of April. These figures highlight the strength and scalability of Cantourage's business model, alongside robust market demand.

As Europe's leading listed medical cannabis company, Cantourage operates in various segments, including dried flowers, extracts, dronabinol, and cannabidiol. The firm, established in 2019, collaborates with over 60 growers from 18 countries, ensuring top-tier pharmaceutical quality across its offerings. Listed on the Frankfurt Stock Exchange since 2022, Cantourage's recent financial performance underscores its growing influence in the European medical cannabis market.